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Abstract
The concept of tissue banking as a “bio-repository” aimed to collection, storing and distribution of human
biological material and clinical information, is emerging as a successful strategy to support clinical and translational
research. In particular, Tumor Biobanks represent a key resource for diagnosis, research and experimental therapies,
especially for those correlated to clinical application of a new type of medicine known as “intelligent drugs”.
Biobanks are not “spontaneous” collections, but they needs an institutional organization, basically a research unit,
whose effectiveness and quality can be guaranteed only if it is carefully organized according to precise and
shared rules.
Background
In recent years, human biological material (e.g. tissues,
cells, nucleic acids) obtained through common diagnos-
tic procedures has become an important resource for
biomedical research. In oncology, tumor tissue samples
represent a precious tool for both clinical and experi-
mental research. These tissues, preserved in optimal
conditions, are an essential resource for identifying novel
biomarkers for specific therapies [1]. Progress in genome
and proteome research has also allowed us to differenti-
ate multifactorial diseases previously considered as a sin-
gle disorder into more precise diagnostic entities [2].
This achievement provides the basis for developing a
more personalized treatment approach, optimizing clin-
ical protocols and improving disease prevention.
However, in order to ascertain the etiology of complex
diseases, it is necessary to have access to a wide collec-
tion of biological samples with epidemiological, clinical,
biological and molecular data from a large number of
patients and healthy persons.
The identification of standard operative procedures
(SOPs) for tissue sampling, storage and collection of
clinical data is an essential step in modern biobank man-
agement [3,4]. Sampling and collecting procedures must
guarantee both the correct pathological diagnosis as well
as the biological integrity of macromolecules (DNA,
RNA and proteins) that represent the potential subject
of investigation. Recently, thanks to the development of
more advanced and sensitive methodologies, attention
has shifted from the use of fresh/frozen tissues to those
fixed in formalin/paraffin-embedded, both of which have
been shown to be reliable sources for molecular analyses
[5]. In addition, today’s biobank requires meaningful,
relevant performance indicators that take into consider-
ation more than just the amount of material collected.
For instance, assessment should also consider the quality
of collected biomaterial and the accompanying data, as
well as the number and quality of projects that have
made use of the material, and the number of resulting
publications (also considering the journal impact factor)
for which the biobank has been the source of tissue
samples.
Biobanking is a new and dynamic discipline that is
being undertaken across a wide range of institutions,
both public and private. The increasing number of bio-
banks has helped create networks across institutions and
countries, these having developed in order to achieve
sufficiently large numbers of tissue samples relating to
the same groups of pathologies. Thanks to international
cooperation, these collections are allowing the study of
rare types of cancers, as well as more common tumours.
Several initiatives have been undertaken that aim to
organize collection of material with reliable clinical in-
formation in order to guarantee high-quality samples ad-
equate for diagnostics, therapy and research. In Europe,
more than 225 biobanks and institutions from over 30
countries that collect samples and pathological/clinical
data belong to the Biobanking and Biomolecular
Resources Research Infrastructure (BBMRI) [6]. The aim
of the BBMRI is to act as an interface between biological
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populations) and high-quality biomedical research. In
this way, the network aims to enhance the scientific ex-
cellence of European biomedical research, increasing the
competitiveness of European biotechnology and attract-
ing investment from global pharmaceutical industries
and research institutions.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All the authors read and approved the final manuscript.
Acknowledgements
We are grateful to Dr. Ornella Sacco, data manager of the Institutional
BioBank of Pascale Hospital (BBI), Naples, Italy.
Received: 25 September 2012 Accepted: 27 September 2012
Published: 2 October 2012
References
1. Oosterhuis JW, Coebergh JW, van Veer EB: Tumour banks: wellguarded
treasures in the interest of patients. Nature Rev Cancer 2003, 3:73–77.
2. Sotiriou C, Piccart MJ: Taking gene-expression profiling to the clinic:
when will molecular signatures become relevant to patient care? Nature
Cancer Rev 2007, 7:545–553.
3. Mager SR, Oomen MHA, Morente MM, Ratcliffe C, Knox K, Kerr DJ, Pezzella
F, Riegman PH: Standard operating procedures for the collection of fresh
frozen tissue samples. Eur J Cancer 2007, 43:828–834.
4. Bell WC, Sexton KC, Grizzle WE: Organizational issues in providing high-
quality human tissues and clinical information for the support of
biomedical research. Methods Mol Biol 2010, 576:1–30.
5. Botti G, Franco R, Carbone A: Sample conservation: freezing, fixation and
quality control. Pathologica 2008, 100:81–85.
6. Asslaber M, Zatloukal K: Biobanks: translational, European and global
networks. Brief Funct Genomic Proteomic 2007, 6:193–201.
doi:10.1093/bfgp/elm023.
doi:10.1186/1479-5876-10-204
Cite this article as: Botti et al.: Tumor biobanks in translational medicine.
Journal of Translational Medicine 2012 10:204.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Botti et al. Journal of Translational Medicine 2012, 10:204 Page 2 of 2
http://www.translational-medicine.com/content/10/1/204
